Myocardial and Arterial Phenotype of Coronary Artery Disease

NCT06202300 | Unknown DMC

• 1 other identifier: KS2023013
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 2

Brief Summary

The CAD-MAP (Myocardial and Arterial Phenotype of Coronary Artery Disease) registry is initiated with the goal to describe the cardiac imaging map including epicardial coronary artery, coronary microcirculation and myocardium, and further exploring the prognostic value of multidimensional imaging biomarkers and predictive models in CAD patients.

Conditions

Coronary Artery Disease

Keywords

Coronary artery disease; Multimodality imaging; Inflammation; Clinical outcome

Outcome Measures

Primary Outcomes (1)

• Major adverse cardiac events (MACEs)

  Including cardiovascular death, nonfatal myocardial infarction, ischemia-driven revascularization

  Median 12 months

Secondary Outcomes (11)

• Major adverse cardiac and cerebrovascular events (MACCEs)

  Median 12 months

• Cardiovascular death

  Median 12 months

• All-cause death

  Median 12 months

• Myocardial infarction

  Median 12 months

• Stroke

  Median 12 months

Study Arms (2)

Patients with high inflammation level

CAD patients undergoing multimodality imaging with high inflammation burden

Other: Inflammation burden

Patients with low inflammation level

CAD patients undergoing multimodality imaging with low inflammation burden

Other: Inflammation burden

Interventions

Inflammation burden OTHER

Coronary artery disease patients undergone multimodality imaging with different level inflammation burden

Patients with high inflammation level; Patients with low inflammation level

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with suspected or confirmed CAD who are eligible to undergo coronary angiography and IVUS/OCT or functional tests.

You may qualify if:

• \. Age ≥18 years old.
• \. Patients with suspected or confirmed coronary artery disease who are eligible to undergo coronary angiography and IVUS/OCT or functional examination.
• \. Written informed consent.
• \. Subject is willing to comply with all protocol-required follow-up evaluation.

You may not qualify if:

• \. Malignant tumor, lymphoma, HIV-positive, or cirrhosis with life expectancy \<1 year.
• \. Pregnancy, lactation, or potentially fertile women.
• \. Patients who cannot complete this trial or comply with the protocol.

Sponsors & Collaborators

• Beijing Anzhen Hospital: lead

Study Sites (2)

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, 100029, China

RECRUITING

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease; Inflammation

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Xiao Wang, MD

  Beijing Anzhen Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiao Wang, MD

CONTACT

86-10-84005253; spaceeye123@126.com

Yingying Guo, MD

CONTACT

86-10-84005253; ying15836089137@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: January 1, 2024
• First Posted: January 11, 2024
• Study Start: March 12, 2023
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2024
• Last Updated: January 11, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)